Abstract: The present invention provides a new use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative thereof. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including MMPs and TIMPs, and so it can inhibit liver fibrosis. In the liver, it can inhibit collagen synthesis and expression, and therefore reverse and treat hepatitis and liver cirrhosis effectively. Also discloses is a method for preparing drugs for treating or preventing infective hepatitis, non-infectious hepatitis, liver injury, liver cirrhosis, liver cancer and liver fibrosis, and protecting and improving the liver function, in which the compound is used alone or in combination with a target molecule or carrier comprising a vitamin A-coupled liposome.